Lutetium Lu 177 Edotreotide dose-finding for children with SSTR-positive tumors
Official title: A Multicenter, Open-label, Interventional Phase I Trial to Determine the Dose and Evaluate the Pharmacokinetics (PK) and Safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as Monotherapy or Following Standard of Care (SoC) for the Treatment of Somatostatin Receptor-positive Tumors in the Pediatric Population (KinLET).
Run by ITM Solucin GmbH · NCT06441331 · Data updated 2026-11-12
This test gives Lutetium Lu 177 Edotreotide to children ages 2 to under 18 with somatostatin receptor–positive tumors to find a safe pediatric dose and see how the drug behaves in the body.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 24 Months to 18 Years |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | ITM Solucin GmbH Industry-sponsored |
| Drugs / interventions | CAR-T, radiation |
| Locations | 9 sites (Palo Alto, California and 8 other locations) |
| Status | Recruiting |
| Started | September 26, 2025 |
| Main results expected | June 2028 |
| Study ends | April 2034 |
| Registry record updated | October 27, 2026 |
| Trial ID | NCT06441331 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children aged 2 to under 18 with recurrent, progressive, or refractory SSTR-positive NETs, CNS tumors, lymphoma, or other solid tumors who show SSTR expression by immunohistochemistry and uptake on somatostatin receptor imaging and have recovered from prior treatment toxicities are the ideal candidates.
✕Probably not a fit
Patients whose tumors do not express SSTRs or lack uptake on SSTR imaging, those with unresolved toxicities from prior treatments, or those unable to travel to a participating center are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 1, open-label dose-finding trial enrolls pediatric participants (ages 2 to <18) with recurrent, progressive, or refractory somatostatin receptor (SSTR)-positive neuroendocrine, CNS, lymphoma, or other solid tumors. Eligible tumors must show SSTR protein by immunohistochemistry and uptake on somatostatin receptor imaging higher than liver uptake. Participants receive intravenous Lutetium Lu 177 Edotreotide every 8 weeks for up to six doses (about 48 weeks total), with supportive amino acid solution as part of administration. The study focuses on defining the appropriate pediatric dose, characterizing pharmacokinetics, and monitoring safety and tolerability when given alone or following standard-of-care therapy.
Why it matters
Potential benefit: If successful, the treatment could provide a targeted radioactive therapy option that helps control SSTR-positive tumors in children who have limited standard options.
How similar studies have gone: Similar adult trials using 177Lu-labeled somatostatin analogs (for example, 177Lu-DOTATATE) have shown clinical benefit in SSTR-positive neuroendocrine tumors, but pediatric data for Lutetium Lu 177 Edotreotide are limited, so this work builds on adult success but is relatively untested in children.
Who can join: the full rules
Show full inclusion / exclusion criteria
Key Inclusion Criteria: * Participants aged ≥ 2 years and \< 18 years * Confirmed diagnosis somatostatin receptor-positive (SSTR-positive) disease. * Tumor which is relapsed or is refractory to at least one line of previous therapy * Positive SSTR protein expression confirmed by immunohistochemistry of a tumor histology sample * Radioactivity uptake within the primary tumor or metastatic tumor sites measured by locally available SRIs ( 111In-based, 99mTc-based, or 68Ga-based SSTR single-photon emission computed tomography (SPECT)/ computed tomography (CT) or positron emission tomography (PET)/CT imaging, which is higher than the liver uptake) * Participants must have recovered from the acute treatment related toxicities (defined as ≤ grade 1 if not defined in eligibility criteria, excluding alopecia, stable treated electrolyte abnormalities on replacement and stable treated hypothyroidism) of all prior treatment modality prior to entering this trial * In case of sequential treatment followed by SoC or prior therapy, washout period applies before starting targeted RPT Screening Consent Participant/legal guardian is willing to sign a screening consent. The screening consent is to be obtained according to institutional guidelines. Assent, when appropriate, will be obtained according to institutional guidelines. Key Exclusion Criteria: * Known hypersensitivity to Lutetium Lu 177 Edotreotide, DOTA/Edotreotide, or excipients * Previous history of acute leukemia unless in remission for at least two years * Extensive bone/bone marrow involvement as per Investigator's judgement unless peripheral blood stem cells (PBSC) are available at a minimum of 2.5x106 CD34+ cells/kg * Patients who have received previous systemic targeted RPT * Previous treatment with metaiodobenzyl guanidine (MIBG) if the predicted overall exposure is expected to exceed 2 Gy (gray) to the bone marrow or 23 Gy to the kidney. * Previous treatment with external beam radiation therapy (EBRT) if the predicted overall exposure is expected to exceed more than 2 Gy to the bone marrow or 23 Gy to the kidney. * Previous treatment with oncologic immune vaccine or CAR-T cell therapy * Bulky disease in the CNS * Presence of severe renal, hepatic, electrolyte, cardiovascular, or hematological dysfunction * Participants who have received a live-attenuated vaccine up to four weeks prior to enrolment * Pregnant or breastfeeding women. * Other known malignancies. * Serious non-malignant disease.
Where it's running
-
Lucile Packard Children's Hospital at Stanford
Palo Alto, California, United States Recruiting -
UCSF Benioff Children's Hospital
San Francisco, California, United States Recruiting -
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States Recruiting -
The Children's Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania, United States Recruiting -
University of Texas - MD Anderson Cancer Center
Houston, Texas, United States Recruiting -
CHU de Marseille - Hôpital de la Timone
Marseille, France Recruiting
Show 3 more locations
-
Gustave Roussy Cancer Campus
Villejuif, France Recruiting -
Hospital Universitario Vall d'Hebron - Oncología Médica
Barcelona, Spain Recruiting -
Hospital General Universitario Gregorio Marañón
Madrid, Spain Recruiting
Study contacts
- Study coordinator: Pia Zehkorn
- Email: kinlet@itm-radiopharma.com
- Phone: +4989 32989866000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Methionine-Reduced Diet in Solid Tumors (early-phase)
A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.
-
Testing CTS3497 for patients with specific cancer types
This study is testing a new drug called CTS3497 to see if it can help patients with certain hard-to-treat cancers that have not responded to other treatments.
-
Using CAN2109 to treat advanced solid tumors and lymphomas
This study is testing a new treatment called CAN2109 that is injected directly into tumors to see if it can help people with advanced solid tumors and lymphomas feel better.
-
Multidisciplinary support for young cancer survivors
This study is testing whether a special support program can help young cancer survivors aged 15 to 25 feel better and improve their quality of life after finishing treatment.
-
A network for collaborative cancer research in Ontario
This study is testing a new way to improve cancer treatment by using genetics and technology to help personalize care for people with different types of cancer.
-
Evaluating LB1410 for advanced solid tumors and lymphoma
This study is testing a new treatment called LB1410 to see if it is safe and effective for people with advanced solid tumors or lymphoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.